Adial Pharmaceuticals, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Coastlands Capital LP and affiliated entities have reported beneficial ownership of 14.22% of Adial Pharmaceuticals' common stock, totaling 373,322 shares.
NASDAQ
Coastlands Capital LP and affiliates have reported a 9.98% beneficial ownership stake in Adial Pharmaceuticals, Inc. as of June 17, 2026.
NASDAQ
Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, reporting beneficial ownership of 274,139 shares, representing 4.99% of Adial Pharmaceuticals, Inc.'s common stock.
NASDAQ
SCHEDULE 13G: Intracoastal Capital and Affiliates Disclose 2.8% Beneficial Ownership in Adial Pharmaceuticals
Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, has filed a Schedule 13G disclosing a 2.8% beneficial ownership stake in Adial Pharmaceuticals, Inc. common stock.